Actinium Pharmaceuticals, Inc.: appoints chief financial officer

What happened

• Actinium Pharmaceuticals, Inc. announced that Matt David, M.D., age 49, commenced service as chief financial officer and principal financial officer on Oct 14, 2026. The company entered into an offer letter with Dr. David on Sep 30, 2026 and issued a press release on Oct 15, 2026 announcing his appointment.

Key details

• Compensation: annual base salary of $450,000, a target annual performance bonus of 40% of base salary, a $150,000 sign-on bonus, and a guaranteed prorated target bonus for 2026 subject to continued employment.
• Equity and awards: option to purchase 250,000 shares and 325,000 restricted stock units under the company’s 2026 Employment Inducement Award Plan; the option’s exercise price equals the closing market price on the grant date and vests over four years; the RSUs include time-based vesting and performance-based vesting tied to corporate milestones.
• Severance: the offer letter provides customary severance benefits on certain qualifying terminations, including salary continuation, continued health benefits, bonus payments and equity vesting acceleration, with enhanced severance for certain terminations following a change in control.
• Other disclosures: no arrangements or understandings with others regarding his selection, no family relationships with company directors or executive officers, and no material interest in transactions required to be disclosed under Item 404(a); the Inducement Plan was adopted by the board on Sep 2, 2026 without stockholder approval pursuant to Section 711(a) of the NYSE American Company Guide.

Why it may matter

• The filing reports an officer appointment under Item 5.02 (departure of directors or certain officers; election of directors) and furnishes a press release under Item 7.01 (Regulation FD disclosure).

This filing does not show why the insider traded or why the company acted.